<DOC>
	<DOCNO>NCT02559778</DOCNO>
	<brief_summary>A prospective open label , multicenter study evaluate feasibility acute toxicity use molecularly guide therapy combination standard therapy follow maintenance therapy DFMO subject newly diagnose high risk neuroblastoma .</brief_summary>
	<brief_title>Pediatric Precision Laboratory Advanced Neuroblastoma Therapy</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Diagnosis : Subjects must diagnosis highrisk ( define protocol ) neuroblastoma ganglioneuroblastoma ( nodular intermixed ) verify histology demonstration clump tumor cell bone marrow elevate urinary catecholamine metabolite . Subjects must age ≤ 21 year initial diagnosis Subjects must prior systemic therapy except localized emergency radiation sit lifethreatening functionthreatening disease and/or 1 cycle chemotherapy per low intermediate risk neuroblastoma regimen ( per P9641 , A3961 , ANBL0531 , similar ) prior determination MYCN amplification status histology . Specimens obtain nonsignificant risk manner solely purpose investigational testing . Adequate liver function must demonstrate ( define protocol ) Subjects must adequate renal function define Serum creatinine base age/gender ( define protocol ) Adequate Cardiac Function ( define protocol ) Ability tolerate PBSC collection : No known contraindication PBSC collection . A negative serum pregnancy test require female participant child bear potential ( ≥13 year age onset menses ) Both male female postpubertal study subject need agree use one effective birth control method treatment six month treatment stop . These method include total abstinence ( sex ) , oral contraceptive ( `` pill '' ) , intrauterine device ( IUD ) , levonorgestrol implant ( Norplant ) , medroxyprogesterone acetate injection ( Depoprovera shot ) . If one use , contraceptive foam condom recommend . Informed Consent : All subject and/or legal guardian must sign informed write consent . Assent , appropriate , obtain accord institutional guideline Subjects 1218 month age INSS Stage 4 stage 3 subject favorable biologic feature ( ie , nonamplified MYCN , favorable pathology , DNA index &gt; 1 ) eligible . Lactating female eligible unless agree breastfeed infant . Subjects receive investigational drug concurrently . Subjects medical condition , include limited malabsorption syndrome , mental illness substance abuse , deem Investigator likely interfere interpretation result would interfere subject 's ability sign legal guardian 's ability sign inform consent , subject 's ability cooperate participate study</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>